ReportsGenetics

Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth

See allHide authors and affiliations

Science  16 Jun 2017:
Vol. 356, Issue 6343, pp. 1188-1192
DOI: 10.1126/science.aag2553

Preparing for the feast during the fast

A protein kinase complex known as mTORC1 plays a key role in cellular metabolism and nutrient sensing. Di Malta et al. elucidated a mechanism that regulates the metabolic changes that are necessary during the fast-to-feed transition. During starvation, a pair of transcription factors promotes the expression of a pair of guanosine triphosphatases that are required for mTORC1 activity and for its recruitment to the lysosome. However, mTORC1 activity also requires amino acids, which are lacking during starvation. Nevertheless, the cell becomes “primed” by this process so that on refeeding, it efficiently reactivates mTORC1, which is recruited to the lysosomal surface. This mechanism is particularly important in cancer cells.

Science, this issue p. 1188

Abstract

The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that MiT/TFE transcription factors—master regulators of lysosomal and melanosomal biogenesis and autophagy—control mTORC1 lysosomal recruitment and activity by directly regulating the expression of RagD. In mice, this mechanism mediated adaptation to food availability after starvation and physical exercise and played an important role in cancer growth. Up-regulation of MiT/TFE genes in cells and tissues from patients and murine models of renal cell carcinoma, pancreatic ductal adenocarcinoma, and melanoma triggered RagD-mediated mTORC1 induction, resulting in cell hyperproliferation and cancer growth. Thus, this transcriptional regulatory mechanism enables cellular adaptation to nutrient availability and supports the energy-demanding metabolism of cancer cells.

A major determinant of species evolution is the ability to switch between anabolic and catabolic pathways in response to nutrient availability. The nutrient-activated kinase complex target of rapamycin complex 1 (mTORC1) promotes biosynthetic processes and inhibits catabolic pathways such as autophagy (1, 2), thus playing a crucial role in the adaptation of the organism to the environment (3, 4). The transcription factors TFEB, TFE3, TFEC, and MITF belong to the MiT-TFE family and bind the same target sites in the proximal promoters of overlapping sets of genes (5, 6). TFEB and TFE3 are master transcriptional regulators of lysosomal biogenesis and autophagy (68), whereas MITF regulates melanosomal biogenesis (9). mTORC1 negatively regulates the activity of these transcription factors by phosphorylating critical serine residues, leading to their cytoplasmic retention (8, 1012). Conversely, during starvation or physical exercise, inhibition of mTORC1 and activation of the phosphatase calcineurin leads to TFEB and TFE3 dephosphorylation and nuclear translocation (13, 14).

We postulated the presence of a feedback loop by which MiT-TFE transcription factors, which are substrates of mTORC1, may in turn influence mTORC1 activity. Small interfering RNA (siRNA)–mediated depletion of either TFEB or TFE3 in HeLa cells significantly decreased mTORC1 activity upon amino acid administration (fig. S1, A and B). Furthermore, mTORC1 reactivation upon prolonged starvation (15) was inhibited in TFEB-silenced cells (fig. S1C). Overexpression of either wild-type or constitutively active TFEB and TFE3 (TFEB-CA and TFE3-CA) resulted in increased mTORC1 activation upon stimulation with either a complete set of amino acids (figs. S1, D to I, and S2) or solely leucine or arginine, the key amino acids that activate mTORC1 (16) (Fig. 1, A and B). Consistently, viral-mediated TFEB overexpression in the liver of wild-type mice increased mTORC1 signaling (Fig. 1, C and D). Conversely, a significant reduction in the rate of protein synthesis and impaired mTORC1 signaling were detected in the livers from TFEB liver-specific conditional knockout (KO) mice (Tcfebflox/flox; Alb-CRE+; hereafter Tcfeb-LiKO) (Fig. 1E). In addition, exercised muscle-specific TFEB KO mice (Tcfebflox/flox; Mlc-CRE+; hereafter Tcfeb-MuKO) showed a reduced induction of mTORC1 activity and protein synthesis in response to leucine after exercise (Fig. 1F). Thus, the effect of a protein meal after exercise on muscle protein synthesis requires TFEB-induced activation of mTORC1 signaling.

Fig. 1 MiT/TFE transcription factors regulate mTORC1 activity both in vitro and in vivo.

(A and B) Representative immunoblots of TFEB, phospho-S6K, and S6K in Tet-ON TFEB-CA cell line untreated (–DOX) or treated with doxycycline (+DOX) for 24 hours. Cells were starved for amino acids for 50 min (0) and stimulated with decreasing levels (expressed as % of concentration in RPMI medium) of leucine (A) or arginine (B) for 20 min. (C) C57BL6 mice injected with HDad expressing human TFEB under the control of a liver-specific promoter (TFEB-INJ) or with phosphate-buffered saline (PBS) (CTRL) were starved for 22 hours (FASTED) and then refed for 2 hours (FED). Liver lysates were analyzed for levels of indicated proteins. Actin was used as loading control. Plot shows ratio of phosphorylated S6K/pan-S6K (mean of three independent experiments). (D) Immunohistochemistry of liver sections from mice injected with saline PBS (CTRL) or HDAd-TFEB (TFEB-INJ). Tissues were stained for serine 240/244 phosphorylated-S6 (P-S6). Insets show overlapping P-S6 and TFEB immunostainings in two consecutive 5-μm liver sections isolated from HDad-TFEB–injected mice. (E) Liver samples from mice with indicated genotypes were analyzed for the levels of S6K phosphorylation and puromycin incorporation. Plots show the ratios of phosphorylated S6K/pan-S6K and puromycin/actin expressed as relative to control mice (Tcfebflox/flox). (F) Phosphorylation of S6K and levels of puromycin incorporation analysis in muscle samples from mice with indicated genotypes after oral gavage of leucine. Mice were exercised where indicated. Plots show ratios of phosphorylated S6K/pan-S6K and puromycin/glyceraldehyde phosphate dehydrogenase (GAPDH). Plots in (C) and (E) represent means of triplicates ± SEM, Student’s t test. Plots in (F) represent means ± SEM; N = 3/condition; one-way analysis of variance (ANOVA) followed by Tukey’s test. [(C), (E), and (F)]: *P < 0.05; **P < 0.01; ***P < 0.001.

TFEB overexpression in cells lacking the essential autophagy genes Atg5 or Atg7 still resulted in enhanced mTORC1 activity, similar to wild-type cells (fig. S3). Thus, MiT-TFE transcription factors may regulate mTORC1 by a mechanism that is different from autophagy. To identify such a mechanism, we searched for TFEB DNA binding sites, defined as “CLEAR elements” (6), in the promoters of 50 human genes known to play a role in the activation of mTORC1. Among 20 TFEB/TFE3 putative target genes (tables S1 and S2), the transcript levels of the guanosine triphosphatase (GTPase) RagD were the most significantly decreased upon single or combined TFEB or TFE3 silencing (fig. S4, A to C). Conversely, RagD was strongly induced in TFEB-overexpressing cells both at the mRNA (Fig. 2A and fig. S4D) and protein (fig. S4, E and F) levels. An induction of RagD expression was also detected in liver samples from mice injected with helper-dependent adenovirus (HDad) containing TFEB or TFE3 (fig. S4G), and a reduction of RagD expression was observed in TFEB LiKO and TFE3 full-KO mice (fig. S4H). To exert their activity, RagD and RagC need to heterodimerize with RagA or RagB and to be activated by folliculin (FLCN), a GTPase activating protein (GAP) (17). RagC and FLCN expression levels were also influenced by MiT-TFE genes, albeit to a lesser extent compared with RagD (Fig. 2A and fig. S4, A to D). RagD is expressed at very low levels; thus, we postulate that RagD is a limiting factor for Rag GTPase activity.

Fig. 2 MiT/TFE transcription factors control mTORC1 activity through RagD.

(A) mRNA levels of mTORC1-related genes in TFEB-CA HeLa cells treated with doxycycline. Values normalized relative to HPRT1 and expressed as fold change relative to untreated cells. (B) ChIP analysis of TFEB binding to RagD promoter in doxycycline-treated HeLa TFEB-CA cells. Squares represent CLEAR sites in RagD promoter and numbers refer to their distance [in base pairs (bp)] from the transcriptional start site (TSS). Immunoprecipitated DNA was normalized to the input and plotted as relative enrichment over a mock control. (C) Luciferase assay after transfection of increasing amounts of TFEB construct was performed in HeLa cells cotransfected with wild-type (RAGD-wt) or mutated (RAGD-mut) RagD-promoter luciferase reporter plasmids. (D) Scheme of CRISPR-Cas9–mediated mutation in the endogenous RagD promoter of HeLa cells. A region of 33 bp containing the CLEAR site at position –284 (in red) was ablated. (E) Transcript levels of Rags and Flcn genes were analyzed in the mutated HeLa cell line (HeLa-RagDpromedit) versus control HeLa and normalized relative to HPRT1 gene. (F) Immunoblots of mTORC1 signaling in HeLa-RagDpromedit cells compared with control HeLa. The ratio of phosphorylated/total protein levels shown for the indicated mTORC1 substrates. Plots in (A), (B), (C), (E), and (F) represent mean ± SEM of three independent experiments (Student’s t test). (G) Mice with indicated genotypes were nutritionally synchronized and injected with puromycin 30 min before sacrifice. Where indicated, Tcfebflox/flox;Alb-Cre+ mice were injected with an adeno-associated virus vector carrying human RagD cDNA. Liver lysates were analyzed for phosphorylation of S6K and levels of puromycin incorporation. Plots show means of triplicates ± SEM, one-way ANOVA expressed as ratio of phosphorylated S6K/pan-S6K and puromycin/actin. [(A), (B), (C), (E), (F), and (G)]: *P < 0.05; **P < 0.01; ***P < 0.001.

Chromatin immunoprecipitation (ChIP) and luciferase assay experiments revealed that RagD is a direct transcriptional target of TFEB (Fig. 2, B and C). Thus, we used a clustered regularly interspaced short palindromic repeats–Cas9 (CRISPR-Cas9)–mediated genome-editing approach to delete the most responsive TFEB target site in the RagD proximal promoter region in HeLa cells (HeLa-RagDpromedit) (Fig. 2D). This cell line showed significantly reduced transcript and protein levels of RagD—whereas other mTORC1-related genes were not affected (Fig. 2E and fig. S5A)—as well as a significant impairment of mTORC1 activation upon amino acid stimulation (Fig. 2F and fig. S5, B and C). Overexpression of exogenous RagD rescued mTORC1 signaling in the HeLa-RagDpromedit cell line (fig. S5D). Consistently, viral-mediated RagD gene delivery rescued impaired mTORC1 signaling and defective protein synthesis in the livers of Tcfeb‐LiKO mice (Fig. 2G). Thus, the transcriptional regulation of RagD expression by MiT-TFE transcription factors plays an important role in the control of mTORC1 activity.

TFEB and TFE3 are activated by starvation (7, 8). Consistently, we observed an increase of RagD mRNA and protein levels during starvation, which was blunted by silencing of either TFEB or TFE3 (fig. S6, A and B). In addition, we found a significant correlation between starvation-induced TFEB nuclear localization and RagD expression levels (fig. S6, C and D). Accordingly, fasting and physical exercise in mice induced RagD expression in liver and muscle, which was blunted in TFEB LiKO and MuKO mice, respectively (fig. S6, E and F). Nutrients induce mTORC1 recruitment to the lysosomal surface via the interaction of Rag GTPases with the Raptor subunit of the mTORC1 complex (18, 19). We detected an increase of amino acid–induced mTORC1 recruitment to the lysosome in TFEB-CA overexpressing cells compared with wild-type cells (fig. S7), whereas an opposite effect was observed in TFEB-depleted cells, as well as in the HeLa-RagDpromedit cell line (Fig. 3, A and B), which was rescued by RagD overexpression (Fig. 3A). Thus, TFEB-mediated control of RagD promotes the efficient recruitment of mTORC1 to the lysosome.

Fig. 3 MiT/TFE transcription factors promote lysosomal recruitment of mTOR upon nutrient loading.

(A) Representative immunofluorescence images of endogenous mTOR, LAMP1-GFP (visualized as red) and RAGD-HA in HeLa cells. Cells were transfected with scramble (CTRL) or with TFEB siRNA (siTFEB) and after 48 hours with LAMP1-GFP and with RagD-HA plasmids for an additional 24 hours. (B) Representative immunofluorescence images of mTOR and LAMP2 in HeLa-RagDpromedit and in control HeLa cells. [(A) and (B)] Cells were deprived of amino acids for 50 min and then stimulated with amino acids for 15 min. Plots represent quantification of the data from 15 cells per condition from three independent experiments. Results are shown as means of colocalization coefficient of (A) mTOR and LAMP1 ± SEM (one-way ANOVA) and (B) mTOR and LAMP2 ± SEM (Student’s t test). **P < 0.01; ***P < 0.001. Scale bars, 10 μm.

MiT-TFE are known oncogenes overexpressed in a variety of tumors such as renal cell carcinoma (RCC), melanoma, sarcoma, and pancreatic ductal adenocarcinoma (2022). TFEB kidney-specific conditional overexpressing mice display a phenotype that closely recapitulates human RCC (23). We observed hyperactivation of mTORC1 signaling and increased RagD transcript levels in both kidney tissues and primary kidney cells from these mice (fig. S8, A to C). Treatment with the mTORC1 inhibitor Torin 1 fully rescued the hyperproliferative phenotype of primary kidney cells (fig. S8D). Similarly, kidney cells derived from a patient with RCC carrying a chromosomal translocation that involves the TFE3 gene (HCR-59) showed increased RagD transcript levels and enhanced mTORC1 signaling (Fig. 4, A and B). Notably, silencing of either TFE3 or RagD rescued mTORC1 hyperactivation and reduced tumor cell proliferation (fig. S8, E and F, and Fig. 4C). Furthermore, a survey of RNA sequencing data obtained from patients with RCC carrying TFE3 chromosomal translocations revealed a consistent increase of RagD expression levels (fig. S8G) (24). We also analyzed cell lines from patients with pancreatic ductal adenocarcinoma (PDA) in which MiT/TFE genes are up-regulated (22) and found increased RagD levels (fig. S9, A and B). Silencing of TFE3 in two of these cell lines decreased RagD levels and rescued mTORC1 hyperactivation (fig. S9, C to F).

Fig. 4 Deregulation of the MiT/TFE-RagD-mTORC1 regulatory axis supports cancer growth.

(A) mRNA levels of RagD in a cell line from a patient with RCC (HCR-59) relative to control kidney cells (HK-2). B2M expression shown as control unrelated gene. Gene expression was normalized relative to HPRT1. Plot represents means of three independent experiments ± SEM; Student’s t test. (B) Analysis of S6K phosphorylation at threonine 389 in HK-2 and HCR-59 cells 50 min starved for amino acids (0) and then stimulated with increasing levels of amino acids for 20 min. (C) Proliferation levels of HCR-59 cells transfected with scramble (SCR), RagD, or TFE3 siRNAs. Plot represents means of three independent experiments ± SEM; one-way ANOVA. (D) MITF-dependent melanoma patient–derived cells (501Mel) were analyzed for mRNA levels of RagD (B2M expression was shown as control unrelated gene). Values expressed as relative to control melanoma cells (A375P). Gene expression was normalized relative to HPRT1. Plot represents means of three independent experiments ± SEM (Student’s t test). (E) Representative immunoblotting analysis for the indicated proteins in control (A375P) and MITF-dependent melanoma (501Mel) cells stimulated with increased levels of amino acids. (F) Proliferation index of 501Mel cells transfected with SCR, RagD, or MITF siRNAs. Plot represents means of three independent experiments ± SEM; one-way ANOVA. (G and H) 501Mel cells were infected with a lentivirus expressing a short hairpin RNA targeting the Luciferase (control, Sh-Luc) or RagD mRNAs and transplanted in NOD scid gamma (NSG) mice. (G) Representative picture of tumors isolated from both groups of mice. (H) Plot shows tumor volumes. Each dot represents a tumor. Twelve tumors (n = 12 mice) were analyzed per group; Student’s t test. [(A), (C), (D), (F), and (H)]: **P < 0.01, ***P < 0.001.

MITF, another member of the MiT/TFE family, is an established oncogene in melanoma (25). Transient overexpression of MITF in HeLa cells induced up-regulation of RagD transcript levels and increased mTORC1 activation (fig. S9, G and H), indicating that MITF is also able to positively regulate RagD expression. Consistently, a cell line from a patient with melanoma, associated with high levels of MITF, 501Mel, showed induction of RagD expression and increased mTORC1 activation (Fig. 4, D and E). Notably, silencing of RagD was sufficient to significantly revert the hyperproliferative phenotype of this tumor cell line (Fig. 4F). In addition, a survey of published microarray data available for melanoma metastatic patients (The Cancer Genome Atlas data set) and melanoma cell lines (Gene Expression Omnibus database) revealed a significant correlation between MITF and RagD gene expression levels (fig. S9, I and J). Importantly, xenotransplantation experiments performed using the 501Mel melanoma cell line showed markedly reduced xenograft tumor growth upon RagD silencing, demonstrating a key role of RagD in promoting tumor growth (Fig. 4, G and H). In conclusion, we identified an MiT/TFE-RagD-mTORC1-MiT/TFE feedback circuit, whose fine modulation is critical for metabolic adaptation to nutrient availability. Deregulation of this mechanism supports cancer metabolism, thus promoting tumor growth (fig. S10).

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/356/6343/1188/suppl/DC1

Materials and Methods

Figs. S1 to S10

Tables S1 and S2

References (2630)

References and Notes

  1. Acknowledgments: We are grateful to M. A. De Matteis, G. Diez-Roux, and G. Napolitano for helpful suggestions. We thank A. Salzano and E. De Gennaro for technical assistance. This work was supported by grants from the Italian Telethon Foundation (TGM11CB6); MIUR FIRB RBAP11Z3YA (A.B.); European Research Council Advanced Investigator grant no. 250154 (CLEAR) and no. 694282 (LYSOSOMICS) (A.B.) and no. 341131 (InMec) (P.G.P.); U.S. National Institutes of Health (R01-NS078072) (A.B.); and the Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) to A.B (IG 2015 Id 17639) and C.S. (IG 2015 Id 17717). All data needed to evaluate the conclusions in the paper are present in the paper and/or the supplementary materials.
View Abstract

Navigate This Article